Rhabdomyolysis due to interaction of simvastatin with mibefradil.
Schmassmann-Suhijar
D
D
Bullingham
R
R
Gasser
R
R
Schmutz
J
J
Haefeli
W E
WE
D000368:Aged; D000369:Aged, 80 and over; D000924:Anticholesteremic Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D001562:Benzimidazoles / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D004347:Drug Interactions; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D020748:Mibefradil; D008862:Microsomes, Liver / Q000187:drug effects; D012206:Rhabdomyolysis / Q000139:chemically induced*; D019821:Simvastatin / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D013764:Tetrahydronaphthalenes / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D001562:Benzimidazoles; D002121:Calcium Channel Blockers; D013764:Tetrahydronaphthalenes; D020748:Mibefradil; D019821:Simvastatin